Quoin reports QRX003 trial results in Netherton Syndrome

• Quoin Pharmaceuticals reported positive interim Phase 2/3 data for QRX003 4% lotion in patients with Netherton Syndrome.
• Four of six participants achieved at least a one-grade improvement in Investigator Global Assessment after 12 weeks.
• Quoin said it plans to complete enrollment by the end of 2026 and report topline data in the second quarter of 2027.

Quoin Pharmaceuticals (NASDAQ:QNRX) reported positive interim results from its Phase 2/3 CL-QRX003-004 study showing QRX003 4% lotion met its primary endpoint in the first six participants with Netherton Syndrome.

The open-label study showed four of six participants, or 66.67%, achieved at least a one-grade improvement in Investigator Global Assessment across all treated areas after 12 weeks, with statistical significance compared with the company’s predefined threshold.

The study’s key secondary endpoint also reached statistical significance at Week 12, with the Global Statistical Test of Global Impression of Change showing a mean change of -1.5, while all three participants with moderate to severe pruritus at baseline achieved at least a three-grade improvement in Worst Itch Numeric Rating Scale scores.

The company stated it expects to complete enrollment of approximately 20 evaluable participants by the end of 2026.

Four of six participants reported more than 25% reductions in Ichthyosis Area and Severity Index scores, with improvements ranging from 31% to 87% from baseline, while QRX003 was generally well tolerated with no treatment-related serious adverse events reported.

Quoin Pharmaceuticals said it plans to release topline results from the Phase 2/3 study in the second quarter of 2027 as it continues evaluating QRX003 for Netherton Syndrome, a rare genetic skin disorder.